{"database": "open_comments", "table": "documents", "rows": [["FDA-2011-D-0611-0094", "FDA", "FDA-2011-D-0611", "New and Revised Draft Q&As on Biosimilar Development and the BPCI Act (Revision 4) Guidance for Industry - \nDraft Guidance", "Other", "Guidance", "2026-03-10", 2026, 3, "2026-03-10", "2026-05-12", "2026-03-14 09:00:14", null, 1, 0, "09000064b92071bb"]], "columns": ["id", "agency_id", "docket_id", "title", "document_type", "subtype", "posted_date", "posted_year", "posted_month", "comment_start_date", "comment_end_date", "last_modified", "fr_doc_num", "open_for_comment", "withdrawn", "object_id"], "primary_keys": ["id"], "primary_key_values": ["FDA-2011-D-0611-0094"], "units": {}, "query_ms": 0.3407031763345003, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}